Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PPM1B | O75688 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21061586 | 0.87 | MAPT (0.43) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL28445060 | 0.86 | MAPT (0.45) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1700730 | 0.82 | MAPT (0.47) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL21743066 | 0.81 | MAPT (0.46) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL28451183 | 0.81 | MAPT (0.46) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL21061853 | 0.79 | MAPT (0.47) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL16089711 | 0.78 | MAPT (0.50) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL9958117 | 0.78 | MAPT (0.50) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12697848 | 0.78 | MAPT (0.44) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL21062057 | 0.77 | RAB9A (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111479813-B | Triazolobenzazepines as vasopressin V1A receptor antagonists | 吉瑞工厂 | 2023-03-21 | — | — | CN | disclosed |
| EP-3724192-B1 | TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2022-08-03 | — | — | EP | disclosed |
| US-11298363-B2 | Triazolobenzazepines as vasopressin V1a receptor antagonists | RICHTER GEDEON NYRT. (HU) | 2022-04-12 | — | — | US | disclosed |
| CN-111479813-A | Triazolobenzazepines as vasopressin V1A receptor antagonists | 吉瑞工厂 | 2020-07-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11298363-B2 | Triazolobenzazepines as vasopressin V1a receptor antagonists | AVPR1B, AVPR1A, AVPR2 | MAPT 2132/4885ALDH1A1 1270/4885CYP3A4 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.